West-Ward Pharmaceuticals
West-Ward is the U.S. operations arm of Hikma responsible for marketing, planning, and distributing products in both the injectable and non-injectable business units.
West-Ward Pharmaceuticals Corp. is a wholly owned, U.S. subsidiary of Hikma Pharmaceuticals PLC, based in Amman, Jordan, and headquartered in London, England. Hikma (HIK.L) develops, manufactures, and markets a broad range of pharmaceutical products spanning 45 countries across the U.S., Europe, Middle East, and North Africa. The business is conducted through 3 segments: branded, injectables, and generics with 27 manufacturing facilities worldwide. Hikma’s revenues for the year 2014 were nearly $1.5 billion globally.
West-Ward is the U.S. operations arm of Hikma responsible for marketing, planning, and distributing products in both the injectable and non-injectable business units. West-Ward is supported by 6 FDA-approved manufacturing facilities across the globe, with two based in the U.S. West-Ward has grown at a rate faster than that of the consolidated company, increasing the importance of the U.S. market to Hikma. In 2014, West-Ward represented 51% of Hikma’s group sales.
West-Ward was established in 1946 as a generic orals manufacturing company. With over 60 years of experience, West-Ward has a longstanding presence in the U.S. oral solid generics market, with a focus on quality manufacturing and high service levels. West-Ward has a broad portfolio with 41 oral products in 103 dosage forms. Some of the products for the non-injectable product line include Doxycycline, Amoxicillin, and Prednisone.
West-Ward became the second largest injectable supplier by volume in the U.S. after the acquisition of Baxter’s Multi-Source Injectables (MSI) division in 2011. Continuing the growth of the injectables business, in 2014, Hikma/West-Ward announced the acquisition of certain assets of Bedford Laboratories (the generic sterile injectables division of Boehringer Ingelheim), thereby adding to its injectable product portfolio. In combination with the existing injectables portfolio and FDA manufacturing facilities in Portugal and Germany, these acquisitions solidified the portfolio and reinforced West-Ward as a full-service generics manufacturer. West-Ward’s injectable product portfolio includes 65 products in 184 dosage forms and strengths, including controlled substances. Some of the injectable products include Fentanyl, Morphine, Phenylephrine, Glycopyrrolate and Argatroban.
Spiro Gavaris (West-Ward vice president, sales and marketing) believes that on the heels of the Bedford transaction, West-Ward has optimized the potential of their combined product portfolio, building stronger customer relationships, and increasing new product launches and product acquisitions with the expanded operating capacity.
“Our expanded capacity and site transferring of products optimizes our outputs and increases production for flexible manufacturing," explains Gavaris.
West-Ward is focused on continuous supply given the span of the global market shortages across the industry. With the acquisition of manufacturing facilities in Portugal, Jordan, Saudi Arabia, and Germany, Hikma/West-Ward has expanded its capacity to produce quality pharmaceuticals.
For more information, visit www.west-ward.com.
